Gerresheimer’s 27% Rally Masks a Creditor Lifeline and a June Deadline That Could Make or Break the Stock

Gerresheimer shares surge 27% but face regulatory probes, Barclays downgrade, and SDAX exit; creditors extend loan maturities to 2026.

The Gerresheimer share price has staged a dramatic recovery, climbing more than 27 percent over the past month to close at €24.54 on Thursday and pushing back above its 100-day moving average. Yet beneath the surface of this technical breakout, the pharmaceutical packaging group remains entangled in a deepening regulatory crisis that has already cost it its SDAX listing and drawn the attention of multiple watchdogs.

Barclays has become the latest institution to recalibrate its view. Analyst Jonathon Unwin downgraded the stock from “Equal Weight” to “Underweight” and slashed the price target from €23 to €19, citing the opaque capital structure and the ongoing investigations. The bank now prefers makers of injection systems such as Ypsomed within the sector.

The root of the turmoil lies in accounting irregularities that first surfaced around so-called “bill-and-hold” transactions. Gerresheimer booked revenue prematurely while goods remained undelivered, and an independent probe confirmed systematic violations of IFRS rules that distorted revenue by €35 million and adjusted operating profit by €24 million. The BaFin has since widened its probe to three additional areas: roughly €65 million in misstated lease liabilities, incorrect useful lives assigned to capitalised development costs, and a failure to recognise impairment charges in the Advanced Technologies segment, where the book value stands at nearly €196 million.

The regulatory heat has also turned on the company’s auditor. The Abschlussprüferaufsichtsstelle APAS has opened professional disciplinary proceedings against KPMG, which issued an unqualified audit opinion on the 2024 financial statements despite the IFRS errors. The mandate had been taken over from Deloitte only shortly before.

Despite the mounting pressure, Gerresheimer’s creditors have offered a crucial breathing space. Holders of 96 percent of the company’s €870 million Schuldschein loan volume agreed to extend maturities until the end of September 2026. The banking syndicate has also suspended key leverage covenants until the third quarter.

The company’s forced exit from the SDAX on April 10, triggered by its failure to file a certified annual report by the end of March, has created technical selling pressure as index-tracking funds unwind their positions. The stock was still trading near €25 at the end of April before the recent rally.

Management is pursuing a sale of the US subsidiary Centor as a financial anchor. Morgan Stanley is running the bidding process for the division, which was carried at roughly €300 million on the books at the end of 2024. A deal is expected within the current year, though it would strip the group of a highly profitable unit.

The shareholder protection association DSW is meanwhile examining potential damages claims against former CEO Dietmar Siemssen and former CFO Bernd Metzner.

Operationally, the board has held its ground. The 2026 guidance remains intact, with revenue targeted at up to €2.4 billion and an adjusted operating margin of around 18 percent.

The market’s attention, however, is fixed on June, when Gerresheimer plans to deliver both the audited 2025 annual report and first-quarter figures. Until those documents are certified and on the table, institutional investors lack a reliable foundation for their models, leaving the stock at the mercy of regulatory headlines and balance-sheet revelations. The half-year report is scheduled for July 14. On a 12-month view, the shares remain nearly 60 percent below their level of a year ago.